A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery
Metrics: PDF 617 views | HTML 1057 views | ?
Di Wang1,*, Xin-lu Yang1,*, Xiao-qing Chai1, Shu-hua Shu1, Xiao-lin Zhang1, Yan-hu Xie1, Xin Wei1, Yu-jing Wu2, Wei Wei2
1Department of Anesthesiology, Affiliated Provincial Hospital of Anhui Medical University, Anhui Provincial Hospital, Hefei 230001, China
2Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, China
*These authors have contributed equally to this work
Xiao-qing Chai, e-mail: firstname.lastname@example.org
Keywords: dendritic cells, flurbiprofen, PGE2, esophageal carcinoma, esophageal resection surgery
Received: October 21, 2015 Accepted: February 14, 2016 Published: February 24, 2016
The present study evaluated whether flurbiprofen increased the naturally circulating dendritic cells (DCs) subsets in patients with esophageal squamous cell carcinoma (ESCC) undergoing esophageal resection. Compared to healthy donors (n=20), the significantly depressed percentages of plasmacytoid DCs (pDCs), CD1c+ myeloid DCs (mDCs), and CD141+ mDCs among ESCC patients (n=60) were confirmed. Flurbiprofen was administered before skin incision and at the end of operation in group F (n=30), as well as placebo in group C (n=30). The postoperative suppressed percentages of pDCs, CD1c+ mDCs, and CD141+ mDCs increased significantly following the perioperative treatment with flurbiprofen. Flurbiprofen also significantly stimulated the postoperative IFN-f and IL-17 production, but inhibited the immunosuppressive IL-10 and TGF-β levels. Furthermore, flurbiprofen exerted a similar analgesic effect and brought a significantly less sufentanil consumption compared to group C. Taken together, flurbiprofen provided a short-term increase of postoperative naturally circulating DCs in ESCC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.